Cyclic Amide MetAP-2 Inhibitors for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, inflammation, and obesity lack effective inhibitors of methionine aminopeptidase-2 (MetAP-2), which are crucial for regulating cell processes and angiogenesis, and existing compounds have limitations in efficacy and tolerability.
Innovation Solution
Development of novel compounds of the formula I, which are potent MetAP-2 inhibitors with a specific regulatory, modulatory, and inhibiting action, particularly targeting the MetAP-2 subtype, exhibiting significant activity as medicaments for cancer, fat metabolism, and inflammation, with the S enantiomer showing greater activity than the R enantiomer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MetAP-2 inhibitors are used for cancer treatment, then some inhibitory activity is achieved, but efficacy and tolerability are limited
Solution Approach 1:
The patent modifies the chemical structure of MetAP-2 inhibitors by changing parameters such as the hydroxyl group substitution pattern on the pyrrolidinone ring, the nature of the N-substituent, and the carbonyl group position. These parameter changes in the molecular structure lead to improved inhibitory activity against MetAP-2 while maintaining or reducing toxic effects, thus resolving the contradiction between efficacy and tolerability
Solution Approach 2:
The invention creates composite molecular structures combining specific pyrrolidinone core with various substituent groups (aromatic rings, heterocycles, alkyl chains). This composite approach allows optimization of the pharmacological profile by combining the essential MetAP-2 binding motif with modifying groups that enhance selectivity and reduce off-target effects, improving both efficacy and tolerability
2Reliability
If novel compounds with high MetAP-2 inhibitory activity are developed, then biological activity is improved, but complexity of compound structure increases
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a core pyrrolidinone structure essential for MetAP-2 binding, and separate substituent groups (N-substituents, hydroxyl groups, aromatic rings) that can be independently optimized. This segmentation allows systematic improvement of biological activity by modifying individual segments without redesigning the entire molecule, managing structural complexity effectively
Solution Approach 2:
The invention applies local quality by placing specific functional groups at particular positions on the pyrrolidinone ring (e.g., hydroxyl groups at specific positions, N-substituents on the nitrogen atom). This localized modification approach enables precise tuning of biological activity by optimizing the interaction between specific local features of the molecule and the MetAP-2 active site, rather than requiring complex global structural changes
Data Source
AI summary
Described are cyclic amide compounds of the formula (I):in which R1, R3, R5, R6, R7, R, X and Y have the meanings as described. The compounds are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.